Clinical Trials associated with Shandong First Medical University Affiliated Tumor Hospital (Shandong Cancer Research Institute Shandong Tumor Hospital)
ChiCTR2500099895
/ SuspendedPhase 1IIT
A randomized controlled clinical study comparing the effects of denosumab and teriparatide on lumbar spinal fusion and systemic bone loss after surgery
A Multicenter, Randomized, Controlled, Prospective Clinical Trial on Neoadjuvant Radiotherapy Combined with Cadonilimab, Oxaliplatin, and Capecitabine (XELOX) for Locally Advanced Gastric Cancer
A comparison of the incidence of infective endocarditis and prosthetic valve dysfunctions after aortic valve replacement in One-way limiting expandable artificial biological heart valve and mechanical heart valve
100 Clinical Results associated with Shandong First Medical University Affiliated Tumor Hospital (Shandong Cancer Research Institute Shandong Tumor Hospital)
Login to view more data
0 Patents (Medical) associated with Shandong First Medical University Affiliated Tumor Hospital (Shandong Cancer Research Institute Shandong Tumor Hospital)
Login to view more data
100 Deals associated with Shandong First Medical University Affiliated Tumor Hospital (Shandong Cancer Research Institute Shandong Tumor Hospital)
Login to view more data
100 Translational Medicine associated with Shandong First Medical University Affiliated Tumor Hospital (Shandong Cancer Research Institute Shandong Tumor Hospital)
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.